Pharsight

Astrazeneca patents expiration

1. Airsupra patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Jan 10, 2026

Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient

Market Authorisation Date: 10 January, 2023

Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

AIRSUPRA family patents

Family Patents

2. Bevespi Aerosphere patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716753 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

US9463161 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists and associated methods and systems
May, 2030

(5 years from now)

US8324266 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

US8808713 ASTRAZENECA Compositions for pulmonary delivery of long-acting β2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

US8703806 ASTRAZENECA Compositions, methods and propellant-based systems for respiratory delivery of glycopyrrolate and one or more active agents
May, 2030

(5 years from now)

US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

US8815258 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
Mar, 2031

(6 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Product(NP) Apr 25, 2019

Drugs and Companies using FORMOTEROL FUMARATE; GLYCOPYRROLATE ingredient

Market Authorisation Date: 25 April, 2016

Treatment: Use for the maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

BEVESPI AEROSPHERE family patents

Family Patents

Stay ahead of others in designing the generic launch strategy of these 5 blockbuster drugs expiring in next 5 years.

Get the exclusive patent insights now. Don't be the last to know.

3. Brilinta patents expiration

BRILINTA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US6251910 ASTRAZENECA 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Jul, 2018

(5 years ago)

US7250419 ASTRAZENECA Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Dec, 2019

(4 years ago)

US6525060 ASTRAZENECA Triazolo(4,5-d)pyrimidine compounds
Dec, 2019

(4 years ago)

US7265124 ASTRAZENECA Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
Jul, 2021

(2 years ago)

USRE46276 ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Oct, 2024

(4 months from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6251910 ASTRAZENECA 1,2,3-triazolo[4,5-d]pyrimidines as P2T receptor antagonists
Jul, 2018

(5 years ago)

US6525060 ASTRAZENECA Triazolo(4,5-d)pyrimidine compounds
Dec, 2019

(4 years ago)

US7250419 ASTRAZENECA Trisubstituted triazolopyrimidines for use in platelet aggregation inhibition
Dec, 2019

(4 years ago)

US7265124 ASTRAZENECA Cristalline and amorphous form of a triazolo (4,5-D) pyridimine compound
Jul, 2021

(2 years ago)

USRE46276

(Pediatric)

ASTRAZENECA Triazolo(4,5-D)pyrimidine compounds
Apr, 2025

(10 months from now)

US8425934 ASTRAZENECA Pharmaceutical compositions
Apr, 2030

(5 years from now)

US8425934

(Pediatric)

ASTRAZENECA Pharmaceutical compositions
Oct, 2030

(6 years from now)

US10300065 ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jan, 2036

(11 years from now)

US10300065

(Pediatric)

ASTRAZENECA Method of treating or prevention of atherothrombotic events in patients with history of myocardial infarction
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-848) Nov 05, 2023
M(M-283) May 09, 2025
Pediatric Exclusivity(PED) Nov 09, 2025
New Indication(I-851) May 28, 2023
New Strength(NS) Sep 03, 2018
New Indication(I-714) Sep 03, 2018
New Chemical Entity Exclusivity(NCE) Jul 20, 2016

Drugs and Companies using TICAGRELOR ingredient

NCE-1 date: 09 November, 2024

Market Authorisation Date: 03 September, 2015

Treatment: Reduction of the rate of thrombotic events in patients with acute coronary syndrome; Reducing the rate of cardiovascular death, myocardial infarction, and stroke in a patient receiving 75-100 mg aspir...

Dosage: TABLET;ORAL

How can I launch a generic of BRILINTA before it's drug patent expiration?
More Information on Dosage

BRILINTA family patents

Family Patents

4. Calquence patents expiration

CALQUENCE's oppositions filed in EPO
CALQUENCE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(2 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

US9796721 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(8 years from now)

US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

US11771696 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)

US10167291 ASTRAZENECA Pharmaceutical composition comprising a crystal form of (S)-4-(8-amino-3-(1-(but-2-ynoyl) pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide
Jul, 2036

(12 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-175) Oct 31, 2024
Orphan Drug Exclusivity(ODE-274) Nov 21, 2026
New Indication(I-817) Nov 21, 2022
New Chemical Entity Exclusivity(NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 31 October, 2017

Treatment: Treatment of adult patients with chronic lymphocytic leukemia; Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with prev...

Dosage: CAPSULE;ORAL

How can I launch a generic of CALQUENCE before it's drug patent expiration?
More Information on Dosage

CALQUENCE family patents

Family Patents

5. Calquence patents expiration

CALQUENCE's oppositions filed in EPO
CALQUENCE IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7459554 ASTRAZENECA Imidazopyrazine tyrosine kinase inhibitors
Nov, 2026

(2 years from now)

US9290504 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

US11059829 ASTRAZENECA Crystal forms of (S)-4-(8-amino-3-(1-(but-2-ynoyl)pyrrolidin-2-yl)imidazo[1,5-a]pyrazin-1-yl)-N-(pyridin-2-yl)benzamide maleate
Jul, 2036

(12 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9758524 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as Btk inhibitors
Jul, 2032

(8 years from now)

US10239883 ASTRAZENECA 4-imidazopyridazin-1-yl-benzamides as BTK inhibitors
Jul, 2032

(8 years from now)

US11771696 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)

US10272083 ASTRAZENECA Methods of treating chronic lymphocytic leukemia and small lymphocytic leukemia using a BTK inhibitor
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Oct 31, 2022

Drugs and Companies using ACALABRUTINIB MALEATE ingredient

NCE-1 date: 31 October, 2021

Market Authorisation Date: 03 August, 2022

Treatment: Treatment of adult patients with mantle cell lymphoma who have received at least one prior therapy; Treatment of adult patients with previously untreated chronic lymphocytic leukemia in combination wi...

Dosage: TABLET;ORAL

More Information on Dosage

CALQUENCE family patents

Family Patents

6. Daliresp patents expiration

DALIRESP's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5712298 ASTRAZENECA Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Jan, 2020

(4 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5712298 ASTRAZENECA Fluoroalkoxy-substituted benzamides and their use as cyclic nucleotide phosphodiesterase inhibitors
Jan, 2015

(9 years ago)

US9468598 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidon as excipient
Feb, 2023

(1 year, 3 months ago)

US8431154 ASTRAZENECA Oral dosage form containing a PDE 4 inhibitor as an active ingredient and polyvinylpyrrolidone as excipient
Feb, 2023

(1 year, 3 months ago)

US8536206 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(2 months ago)

US8604064 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(2 months ago)

US8618142 ASTRAZENECA Process for the preparation of roflumilast
Mar, 2024

(2 months ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-208) Aug 31, 2020
New Strength(NS) Jan 23, 2021
New Dosing Schedule(D-171) Jan 23, 2021
New Chemical Entity Exclusivity(NCE) Feb 28, 2016

Drugs and Companies using ROFLUMILAST ingredient

NCE-1 date: 28 February, 2015

Market Authorisation Date: 23 January, 2018

Treatment: Treatment to reduce the risk of copd exacerbations in patients with severe copd associated with chronic bronchitis and a history of exacerbations

Dosage: TABLET;ORAL

How can I launch a generic of DALIRESP before it's drug patent expiration?
More Information on Dosage

DALIRESP family patents

Family Patents

7. Epanova patents expiration

EPANOVA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9050309 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5792795 ASTRAZENECA Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
May, 2020

(4 years ago)

US5948818 ASTRAZENECA Treatment of inflammatory bowel disease using oral dosage forms of omega-3 polyunsaturated acids
May, 2020

(4 years ago)

US9132112 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(8 months from now)

US9012501 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Feb, 2025

(8 months from now)

US8383678 ASTRAZENECA Type a gelatin capsule containing PUFA in free acid form
Feb, 2025

(8 months from now)

US7960370 ASTRAZENECA Type A gelatin capsule containing PUFA in free acid form
Dec, 2026

(2 years from now)

US9050308 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)

US10117844 ASTRAZENECA DPA-enriched compositions of omega-3 polyunsaturated fatty acids in free acid form
Jan, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 05, 2019

Drugs and Companies using OMEGA-3-CARBOXYLIC ACIDS ingredient

NCE-1 date: 05 May, 2018

Market Authorisation Date: 05 May, 2014

Treatment: Treatment of hypertriglyceridemia; Treatment of severe hypertriglyceridemia (500 mg/dl) in adult patients as an adjunct to diet

Dosage: CAPSULE;ORAL

More Information on Dosage

EPANOVA family patents

Family Patents

8. Faslodex patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6774122 ASTRAZENECA Formulation
Jan, 2021

(3 years ago)

US8329680 ASTRAZENECA Formulation
Jan, 2021

(3 years ago)

US8466139 ASTRAZENECA Formulation
Jan, 2021

(3 years ago)

US7456160 ASTRAZENECA Formulation
Jan, 2021

(3 years ago)

US8466139

(Pediatric)

ASTRAZENECA Formulation
Jul, 2021

(2 years ago)

US8329680

(Pediatric)

ASTRAZENECA Formulation
Jul, 2021

(2 years ago)

US6774122

(Pediatric)

ASTRAZENECA Formulation
Jul, 2021

(2 years ago)

US7456160

(Pediatric)

ASTRAZENECA Formulation
Jul, 2021

(2 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-725) Feb 19, 2019
New Indication(I-749) Aug 25, 2020
New Dosing Schedule(D-126) Sep 09, 2013
M(M-103) May 17, 2014
Pediatric Exclusivity(PED) Mar 09, 2014
M(M-123) Nov 09, 2015

Drugs and Companies using FULVESTRANT ingredient

Market Authorisation Date: 25 April, 2002

Treatment: Treatment of hormone receptor positive metastatic breast cancer in postmenopausal women with disease progression following antiestrogen therapy; Treatment of hr-positive, human epidermal growth factor...

Dosage: SOLUTION;INTRAMUSCULAR

How can I launch a generic of FASLODEX before it's drug patent expiration?
More Information on Dosage

FASLODEX family patents

Family Patents

9. Iressa patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US5770599 ASTRAZENECA Quinazoline derivatives
May, 2017

(7 years ago)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5616582 ASTRAZENECA Quinazoline derivatives as anti-proliferative agents
Jan, 2013

(11 years ago)

US5457105 ASTRAZENECA Quinazoline derivatives useful for treatment of neoplastic disease
Jan, 2013

(11 years ago)

US5770599 ASTRAZENECA Quinazoline derivatives
May, 2017

(7 years ago)

Drugs and Companies using GEFITINIB ingredient

Market Authorisation Date: 05 May, 2003

Treatment: Treatment of non-small cell lung cancer; First-line treatment of patients with metastatic non-small cell lung cancer (nsclc) whose tumors have epidermal growth factor receptor (egfr) exon 19 deletions...

Dosage: TABLET;ORAL

More Information on Dosage

IRESSA family patents

Family Patents

10. Koselugo patents expiration

KOSELUGO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US8178693 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(9 months from now)

US7425637 ASTRAZENECA N3 alkylated benzimidazole derivatives as MEK inhibitors
Mar, 2025

(9 months from now)

US9562017 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(2 years from now)

US9156795 ASTRAZENECA Hydrogen sulfate salt
Dec, 2026

(2 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11813246 ASTRAZENECA Pharmaceutical composition
Mar, 2029

(4 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Apr 10, 2025
Orphan Drug Exclusivity(ODE-288) Apr 10, 2027

Drugs and Companies using SELUMETINIB SULFATE ingredient

NCE-1 date: 10 April, 2024

Market Authorisation Date: 10 April, 2020

Treatment: Treatment of pediatric patients 2 years of age and older with neurofibromatosis type 1 (nf1) who have symptomatic, inoperable plexiform neurofibromas (pn)

Dosage: CAPSULE;ORAL

More Information on Dosage

KOSELUGO family patents

Family Patents

11. Lokelma patents expiration

LOKELMA's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US11406662 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US10413569 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US8802152 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Apr, 2032

(7 years from now)

US9913860 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(9 years from now)

US8877255 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(9 years from now)

US10695365 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Oct, 2033

(9 years from now)

US10300087 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)

US9592253 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6332985 ASTRAZENECA Process for removing toxins from bodily fluids using zirconium or titanium microporous compositions
Mar, 2019

(5 years ago)

US9861658 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US10335432 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US10398730 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US8808750 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US9844567 ASTRAZENECA Microporous zirconium silicate for the treatment of hyperkalemia
Feb, 2032

(7 years from now)

US11738044 ASTRAZENECA Extended use zirconium silicate compositions and methods of use thereof
Oct, 2035

(11 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) May 18, 2023
M(M-261) Apr 24, 2023

Drugs and Companies using SODIUM ZIRCONIUM CYCLOSILICATE ingredient

NCE-1 date: 18 May, 2022

Market Authorisation Date: 18 May, 2018

Treatment: Treatment of hyperkalemia in adults

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of LOKELMA before it's drug patent expiration?
More Information on Dosage

LOKELMA family patents

Family Patents

12. Lynparza patents expiration

LYNPARZA's oppositions filed in EPO
LYNPARZA IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US7151102 ASTRAZENECA Phthalazinone derivatives
Apr, 2022

(2 years ago)

US7981889 ASTRAZENECA Phthalazinone derivatives
Oct, 2024

(4 months from now)

US7449464 ASTRAZENECA Phthalazinone derivatives
Sep, 2027

(3 years from now)

US8247416 ASTRAZENECA Phthalazinone derivative
Sep, 2028

(4 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8912187 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(2 months ago)

US9566276 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(2 months ago)

US9169235 ASTRAZENECA Phthalazinone derivatives
Mar, 2024

(2 months ago)

US8071579 ASTRAZENECA DNA damage repair inhibitors for the treatment of cancer
Aug, 2027

(3 years from now)

US8143241 ASTRAZENECA DNA damage repair inhibitors for treatment of cancer
Aug, 2027

(3 years from now)

US11633396 ASTRAZENECA Immediate release pharmaceutical formulation of 4-[3-(4- cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H- phthalazin-1-one
Oct, 2029

(5 years from now)

US8475842 ASTRAZENECA Immediate release pharmaceutical formulation of 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one
Dec, 2029

(5 years from now)

US8859562 ASTRAZENECA Use of RNAI inhibiting PARP activity for the manufacture of a medicament for the treatment of cancer
Aug, 2031

(7 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-83) Dec 19, 2021
Orphan Drug Exclusivity(ODE) Dec 19, 2021
New Chemical Entity Exclusivity(NCE) Dec 19, 2019

Drugs and Companies using OLAPARIB ingredient

NCE-1 date: 19 December, 2018

Market Authorisation Date: 19 December, 2014

Treatment: Treatment of hr-negative, her-2 negative, gbrca-mutated metastatic breast cancer, who have been treated with chemotherapy in the neoadjuvant, adjuvant, or metastatic setting; Maintenance treatment of ...

Dosage: CAPSULE;ORAL; TABLET;ORAL

How can I launch a generic of LYNPARZA before it's drug patent expiration?
More Information on Dosage

LYNPARZA family patents

Family Patents

13. Nexium patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6875872 ASTRAZENECA Compounds
May, 2014

(10 years ago)

US5877192 ASTRAZENECA Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
May, 2014

(10 years ago)

US5690960 ASTRAZENECA Pharmaceutical formulation of omeprazole
Nov, 2014

(9 years ago)

US6875872

(Pediatric)

ASTRAZENECA Compounds
Nov, 2014

(9 years ago)

US5877192

(Pediatric)

ASTRAZENECA Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
Nov, 2014

(9 years ago)

US5714504 ASTRAZENECA Compositions
Feb, 2015

(9 years ago)

US5690960

(Pediatric)

ASTRAZENECA Pharmaceutical formulation of omeprazole
May, 2015

(9 years ago)

US5714504

(Pediatric)

ASTRAZENECA Compositions
Aug, 2015

(8 years ago)

US5900424 ASTRAZENECA Omeprazole magnesium salt form
May, 2016

(8 years ago)

US5900424

(Pediatric)

ASTRAZENECA Omeprazole magnesium salt form
Nov, 2016

(7 years ago)

US7411070 ASTRAZENECA Form of S-omeprazole
May, 2018

(6 years ago)

US6369085 ASTRAZENECA Form of S-omeprazole
May, 2018

(6 years ago)

US8466175 ASTRAZENECA Form of S-omeprazole
May, 2018

(6 years ago)

US6166213 ASTRAZENECA Omeprazole process and compositions thereof
Oct, 2018

(5 years ago)

US6191148 ASTRAZENECA Omerazole process and compositions thereof
Oct, 2018

(5 years ago)

US6147103 ASTRAZENECA Omeprazole process and compositions thereof
Oct, 2018

(5 years ago)

US7411070

(Pediatric)

ASTRAZENECA Form of S-omeprazole
Nov, 2018

(5 years ago)

US6369085

(Pediatric)

ASTRAZENECA Form of S-omeprazole
Nov, 2018

(5 years ago)

US8466175

(Pediatric)

ASTRAZENECA Form of S-omeprazole
Nov, 2018

(5 years ago)

US6147103

(Pediatric)

ASTRAZENECA Omeprazole process and compositions thereof
Apr, 2019

(5 years ago)

US6191148

(Pediatric)

ASTRAZENECA Omerazole process and compositions thereof
Apr, 2019

(5 years ago)

US6166213

(Pediatric)

ASTRAZENECA Omeprazole process and compositions thereof
Apr, 2019

(5 years ago)

US6428810 ASTRAZENECA Pharmaceutical formulation comprising omeprazole
Nov, 2019

(4 years ago)

US6428810

(Pediatric)

ASTRAZENECA Pharmaceutical formulation comprising omeprazole
May, 2020

(4 years ago)

Drug Exclusivity Drug Exclusivity Expiration
M(M-86) Jun 18, 2012
Pediatric Exclusivity(PED) Dec 18, 2012

Drugs and Companies using ESOMEPRAZOLE MAGNESIUM ingredient

Market Authorisation Date: 27 February, 2008

Treatment: Infant use aged 1 month to less than one year, gerd and erosive esophagitis; Treatment of gastroesophageal reflux disease (gerd), risk-reduction of nsaid-associated gastric ulcer, h. pylori eradicati...

Dosage: FOR SUSPENSION, DELAYED RELEASE;ORAL; CAPSULE, DELAYED REL PELLETS;ORAL

How can I launch a generic of NEXIUM before it's drug patent expiration?
More Information on Dosage

NEXIUM family patents

Family Patents

14. Nexium Iv patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6143771 ASTRAZENECA Compounds
May, 2014

(10 years ago)

US5877192 ASTRAZENECA Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
May, 2014

(10 years ago)

US5877192

(Pediatric)

ASTRAZENECA Method for the treatment of gastric acid-related diseases and production of medication using (-) enantiomer of omeprazole
Nov, 2014

(9 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Dosing Schedule(D-138) Mar 04, 2017
New Indication(I-679) Mar 04, 2017

Drugs and Companies using ESOMEPRAZOLE SODIUM ingredient

Market Authorisation Date: 31 March, 2005

Treatment: The short term treatment (up to 10 days) in pts having gastroesophageal reflux disease (gerd) as an alternative to oral therapy in pts when therapy with nexium capsules is not possible or appropriate

Dosage: INJECTABLE;INTRAVENOUS

How can I launch a generic of NEXIUM IV before it's drug patent expiration?
More Information on Dosage

NEXIUM IV family patents

Family Patents

15. Prilosec patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6166213 ASTRAZENECA Omeprazole process and compositions thereof
Oct, 2018

(5 years ago)

US6191148 ASTRAZENECA Omerazole process and compositions thereof
Oct, 2018

(5 years ago)

US6147103 ASTRAZENECA Omeprazole process and compositions thereof
Oct, 2018

(5 years ago)

US6150380 ASTRAZENECA Crystalline form of omeprazole
Nov, 2018

(5 years ago)

US6147103

(Pediatric)

ASTRAZENECA Omeprazole process and compositions thereof
Apr, 2019

(5 years ago)

US6191148

(Pediatric)

ASTRAZENECA Omerazole process and compositions thereof
Apr, 2019

(5 years ago)

US6166213

(Pediatric)

ASTRAZENECA Omeprazole process and compositions thereof
Apr, 2019

(5 years ago)

US6150380

(Pediatric)

ASTRAZENECA Crystalline form of omeprazole
May, 2019

(5 years ago)

Drugs and Companies using OMEPRAZOLE ingredient

Market Authorisation Date: 05 October, 1995

Treatment: NA

Dosage: CAPSULE, DELAYED REL PELLETS;ORAL

How can I launch a generic of PRILOSEC before it's drug patent expiration?
More Information on Dosage

PRILOSEC family patents

Family Patents

16. Prilosec Otc patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5690960 ASTRAZENECA Pharmaceutical formulation of omeprazole
Nov, 2014

(9 years ago)

US5753265 ASTRAZENECA Multiple unit pharmaceutical preparation
Jun, 2015

(8 years ago)

US5817338 ASTRAZENECA Multiple unit tableted dosage form of omeprazole
Oct, 2015

(8 years ago)

US5900424 ASTRAZENECA Omeprazole magnesium salt form
May, 2016

(8 years ago)

US6428810 ASTRAZENECA Pharmaceutical formulation comprising omeprazole
Nov, 2019

(4 years ago)

US6403616 ASTRAZENECA Chemical process and pharmaceutical formulation
Nov, 2019

(4 years ago)

Drugs and Companies using OMEPRAZOLE MAGNESIUM ingredient

Market Authorisation Date: 20 June, 2003

Treatment: NA

Dosage: TABLET, DELAYED RELEASE;ORAL

How can I launch a generic of PRILOSEC OTC before it's drug patent expiration?
More Information on Dosage

PRILOSEC OTC family patents

Family Patents

17. Pulmicort Flexhaler patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6027714 ASTRAZENECA Formulation for inhalation
Jan, 2018

(6 years ago)

US6287540 ASTRAZENECA Formulation for inhalation
Jan, 2018

(6 years ago)

US7143764 ASTRAZENECA Inhalation device
Mar, 2018

(6 years ago)

US6142145 ASTRAZENECA Inhalation device
May, 2018

(6 years ago)

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 12 July, 2006

Treatment: Maintenance treatment of asthma as prophylactic therapy in adult and pediatric patients six years of age or older, including patients requiring oral corticosteroid therapy for asthma

Dosage: POWDER, METERED;INHALATION

More Information on Dosage

PULMICORT FLEXHALER family patents

Family Patents

18. Pulmicort Respules patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7524834 ASTRAZENECA Sterile powders, formulations, and methods for producing the same
Nov, 2018

(5 years ago)

US6598603 ASTRAZENECA Method for treating respiratory diseases
Dec, 2018

(5 years ago)

US6899099 ASTRAZENECA Method for treating a respiratory disease
Dec, 2018

(5 years ago)

US7524834

(Pediatric)

ASTRAZENECA Sterile powders, formulations, and methods for producing the same
May, 2019

(5 years ago)

US6598603

(Pediatric)

ASTRAZENECA Method for treating respiratory diseases
Jun, 2019

(4 years ago)

US6899099

(Pediatric)

ASTRAZENECA Method for treating a respiratory disease
Jun, 2019

(4 years ago)

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 08 August, 2000

Treatment: Treatment of asthma (maintenance and prophylactic therapy); Once daily treatment of asthma with nebulized budesonide

Dosage: SUSPENSION;INHALATION

How can I launch a generic of PULMICORT RESPULES before it's drug patent expiration?
More Information on Dosage

PULMICORT RESPULES family patents

Family Patents

19. Rhinocort patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6686346 ASTRAZENECA Formulation
Apr, 2017

(7 years ago)

US6986904 ASTRAZENECA Formulation
Apr, 2017

(7 years ago)

US6291445 ASTRAZENECA Low dose budesonide formulations and uses thereof
Apr, 2017

(7 years ago)

US6686346

(Pediatric)

ASTRAZENECA Formulation
Oct, 2017

(6 years ago)

US6291445

(Pediatric)

ASTRAZENECA Low dose budesonide formulations and uses thereof
Oct, 2017

(6 years ago)

US6986904

(Pediatric)

ASTRAZENECA Formulation
Oct, 2017

(6 years ago)

Drugs and Companies using BUDESONIDE ingredient

Market Authorisation Date: 23 March, 2015

Treatment: Nasal treatment of seasonal and perennial allergic rhinitis symptoms

Dosage: SPRAY, METERED;NASAL

How can I launch a generic of RHINOCORT before it's drug patent expiration?
More Information on Dosage

RHINOCORT family patents

Family Patents

20. Seroquel Xr patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5948437 ASTRAZENECA Pharmaceutical compositions using thiazepine
May, 2017

(7 years ago)

US5948437

(Pediatric)

ASTRAZENECA Pharmaceutical compositions using thiazepine
Nov, 2017

(6 years ago)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-575) Oct 08, 2011
New Indication(I-574) Oct 08, 2011
New Dosing Schedule(D-117) Oct 08, 2011
Pediatric Exclusivity(PED) Apr 08, 2012
New Indication(I-576) Oct 08, 2011
New Indication(I-618) Dec 02, 2012

Drugs and Companies using QUETIAPINE FUMARATE ingredient

Market Authorisation Date: 17 May, 2007

Treatment: Treatment of schizophrenia

Dosage: TABLET, EXTENDED RELEASE;ORAL

How can I launch a generic of SEROQUEL XR before it's drug patent expiration?
More Information on Dosage

SEROQUEL XR family patents

Family Patents

21. Symbicort patents expiration

SYMBICORT's oppositions filed in EPO
SYMBICORT IPR and PTAB Proceedings
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US6641800 ASTRAZENECA Pressurized aerosol compositions comprising powdered medicament dispersed in hydrofluoroalkane
Sep, 2012

(11 years ago)

US5972919 ASTRAZENECA Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders, as well as its use and the preparation thereof
Dec, 2012

(11 years ago)

US5674860 ASTRAZENECA Combination of a bronchodilator and a steroidal anti-inflammatory drug for the treatment of respiratory disorders
Oct, 2014

(9 years ago)

US6123924 ASTRAZENECA Pressurized aerosol inhalation compositions
Sep, 2017

(6 years ago)

US6123924

(Pediatric)

ASTRAZENECA Pressurized aerosol inhalation compositions
Mar, 2018

(6 years ago)

US8461211 ASTRAZENECA Use for budesonide and formoterol
Sep, 2018

(5 years ago)

US7897646 ASTRAZENECA Use for budesonide and formoterol
Sep, 2018

(5 years ago)

US7367333 ASTRAZENECA Inhalation device
Nov, 2018

(5 years ago)

US7897646

(Pediatric)

ASTRAZENECA Use for budesonide and formoterol
Mar, 2019

(5 years ago)

US8461211

(Pediatric)

ASTRAZENECA Use for budesonide and formoterol
Mar, 2019

(5 years ago)

US7367333

(Pediatric)

ASTRAZENECA Inhalation device
May, 2019

(5 years ago)

US7967011 ASTRAZENECA Inhalation device
Aug, 2021

(2 years ago)

US7967011

(Pediatric)

ASTRAZENECA Inhalation device
Feb, 2022

(2 years ago)

US10166247 ASTRAZENECA Composition for inhalation
Jan, 2023

(1 year, 4 months ago)

US11311558 ASTRAZENECA Composition for inhalation
Jan, 2023

(1 year, 4 months ago)

US8575137 ASTRAZENECA Composition for inhalation
Jan, 2023

(1 year, 4 months ago)

US7759328 ASTRAZENECA Composition for inhalation
Jan, 2023

(1 year, 4 months ago)

US8143239 ASTRAZENECA Composition for inhalation
Jan, 2023

(1 year, 4 months ago)

US8143239

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(10 months ago)

US11311558

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(10 months ago)

US8575137

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(10 months ago)

US7759328

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(10 months ago)

US10166247

(Pediatric)

ASTRAZENECA Composition for inhalation
Jul, 2023

(10 months ago)

US8875699 ASTRAZENECA Inhaler cap strap
Nov, 2024

(5 months from now)

US8875699

(Pediatric)

ASTRAZENECA Inhaler cap strap
May, 2025

(11 months from now)

US7587988 ASTRAZENECA Inhaler device counter
Apr, 2026

(1 year, 10 months from now)

US7587988

(Pediatric)

ASTRAZENECA Inhaler device counter
Oct, 2026

(2 years from now)

US8387615 ASTRAZENECA Inhaler cap strap
Mar, 2027

(2 years from now)

US8387615

(Pediatric)

ASTRAZENECA Inhaler cap strap
Sep, 2027

(3 years from now)

US8528545 ASTRAZENECA Inhaler device that reduces the risk for miscounting a dosage
Oct, 2028

(4 years from now)

US8616196 ASTRAZENECA Inhalation device and a method for assembling said inhalation device
Apr, 2029

(4 years from now)

US8528545

(Pediatric)

ASTRAZENECA Inhaler device that reduces the risk for miscounting a dosage
Apr, 2029

(4 years from now)

US8616196

(Pediatric)

ASTRAZENECA Inhalation device and a method for assembling said inhalation device
Oct, 2029

(5 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Indication(I-582) Feb 27, 2012
M(M-210) Sep 11, 2020
New Patient Population(NPP) Jan 27, 2020
M(M-214) Dec 20, 2020
Pediatric Exclusivity(PED) Jul 27, 2020

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE DIHYDRATE ingredient

Market Authorisation Date: 21 July, 2006

Treatment: Use for the treatment of asthma; Use for the treatment of chronic obstructive pulmonary disease (copd), including chronic bronchitis and emphysema; Use for reducing exacerbations of chronic obstructiv...

Dosage: AEROSOL, METERED;INHALATION

How can I launch a generic of SYMBICORT before it's drug patent expiration?
More Information on Dosage

SYMBICORT family patents

Family Patents

22. Symbicort Aerosphere patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10716753 ASTRAZENECA Compositions for pulmonary delivery of long-acting muscarinic antagonists or long-acting B2 adrenergic receptor agonists and associated methods and systems
May, 2030

(5 years from now)

US9415009 ASTRAZENECA Compositions, methods and systems for respiratory delivery of two or more active agents
May, 2030

(5 years from now)

Drugs and Companies using BUDESONIDE; FORMOTEROL FUMARATE ingredient

Market Authorisation Date: 28 April, 2023

Treatment: Maintenance treatment of patients with chronic obstructive pulmonary disease (copd)

Dosage: AEROSOL, METERED;INHALATION

More Information on Dosage

SYMBICORT AEROSPHERE family patents

Family Patents

23. Tagrisso patents expiration

TAGRISSO's oppositions filed in EPO
Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US9732058 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(8 years from now)

US11524951 ASTRAZENECA 2-(2,4,5-substituted-anilino)pyrimidine compounds
Jul, 2032

(8 years from now)

US8946235 ASTRAZENECA 2-(2,4,5-substituted-anilino) pyrimidine compounds
Aug, 2032

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10183020 ASTRAZENECA Pharmaceutical compositions comprising AZD9291
Jan, 2035

(10 years from now)

Drug Exclusivity Drug Exclusivity Expiration
Orphan Drug Exclusivity(ODE-176) Apr 18, 2025
Orphan Drug Exclusivity(ODE-337) Dec 18, 2027
New Indication(I-941) Feb 16, 2027
Orphan Drug Exclusivity(ODE-102) Nov 13, 2022
New Indication(I-774) Apr 18, 2021
New Indication(I-853) Dec 18, 2023
Orphan Drug Exclusivity(ODE) Nov 13, 2022
New Chemical Entity Exclusivity(NCE) Nov 13, 2020

Drugs and Companies using OSIMERTINIB MESYLATE ingredient

NCE-1 date: 14 November, 2019

Market Authorisation Date: 13 November, 2015

Treatment: Treatment of patients with locally advanced or metastatic non-small cell lung cancer whose tumors have epidermal growth factor receptor exon 19 deletions or exon 21 l858r mutations in combination with...

Dosage: TABLET;ORAL

How can I launch a generic of TAGRISSO before it's drug patent expiration?
More Information on Dosage

TAGRISSO family patents

Family Patents

24. Truqap patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance.
US10059714 ASTRAZENECA Protein kinase B inhibitors
Oct, 2028

(4 years from now)

US8101623 ASTRAZENECA Substituted pyrrolo[2,3-d]pyrimidine as a protein kinase B inhibitor
Mar, 2030

(5 years from now)

US9487525 ASTRAZENECA Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d]pyrimidin-4-yl) piperidine-4-carboxamide
Apr, 2033

(8 years from now)

These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9006430 ASTRAZENECA Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein
Oct, 2025

(1 year, 4 months from now)

US8809336 ASTRAZENECA Ortho-condensed pyridine and pyrimidine derivatives (e.g., purines) as protein kinases inhibitors
Oct, 2025

(1 year, 4 months from now)

US11760760 ASTRAZENECA Protein kinase B inhibitors
Oct, 2028

(4 years from now)

US10654855 ASTRAZENECA Protein kinase B inhibitors
Oct, 2028

(4 years from now)

US10039766 ASTRAZENECA Crystalline forms of (s)-4-amino-n-(1-(4-chlorophenyl)-3-hydroxypropyl)-1-(7h-pyrrolo[2,3-d] pyrimidin-4-y1) piperidine-4-carboxamide
Apr, 2033

(8 years from now)

Drug Exclusivity Drug Exclusivity Expiration
New Chemical Entity Exclusivity(NCE) Nov 16, 2028

Drugs and Companies using CAPIVASERTIB ingredient

NCE-1 date: 17 November, 2027

Market Authorisation Date: 16 November, 2023

Treatment: Treatment with fulvestrant of hr-pos. her2-neg. locally advanced or metastatic breast cancer with pik3ca/akt1/pten-alteration(s) following progression on endocrine therapy in the metastatic setting or...

Dosage: TABLET;ORAL

More Information on Dosage

TRUQAP family patents

Family Patents

25. Zomig-zmt patents expiration

Drug Patent Number Company Drug Patent Title Drug Patent Expiry Activity Alert
These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US5466699 ASTRAZENECA Indolyl compounds for treating migraine
Nov, 2012

(11 years ago)

US5466699

(Pediatric)

ASTRAZENECA Indolyl compounds for treating migraine
May, 2013

(11 years ago)

Drugs and Companies using ZOLMITRIPTAN ingredient

Market Authorisation Date: 13 February, 2001

Treatment: NA

Dosage: TABLET, ORALLY DISINTEGRATING;ORAL

More Information on Dosage

ZOMIG-ZMT family patents

Family Patents